home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ResMed Inc. Common Stock (NY:RMD)

194.88 -3.55 (-1.79%)

Official Closing Price Updated: 6:30 PM EDT, Jun 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ResMed Inc. Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

19 20 Next >

(RMD) - Analyzing ResMed's Short Interest ↗

December 22, 2023

Via Benzinga

ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices

December 20, 2023

ResMed’s masks with magnets are safe when used in accordance with the updated Instructions for Use

From ResMed Inc.

Via GlobeNewswire

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $17,000 Today ↗

December 14, 2023

Via Benzinga

ResMed Secures Significant Victory in Patent Fight Against New York University

December 11, 2023

From ResMed Inc.

Via GlobeNewswire

Why NYSE:RMD qualifies as a good dividend investing stock. ↗

November 30, 2023

Is RESMED INC (NYSE:RMD) a Good Fit for Dividend Investing?

Via Chartmill

Why the dividend investor may take a look at NYSE:RMD. ↗

November 08, 2023

Analyzing RESMED INC (NYSE:RMD)'s Dividend Potential.

Via Chartmill

Is NYSE:RMD a Good Fit for Dividend Investing? ↗

October 18, 2023

Analyzing RESMED INC (NYSE:RMD)'s Dividend Potential.

Via Chartmill

Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally

December 07, 2023

From ResMed Inc.

Via GlobeNewswire

Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion ↗

November 17, 2023

Sen. Tommy Tuberville bought 3 tranches of put options to sell Tesla shares at $190 a day ahead of Q3 results that set in motion a stock slump.

Via Benzinga

ResMed Adopts New Operating Model to Accelerate Long-term Growth

November 09, 2023

From ResMed Inc.

Via GlobeNewswire

Expert Ratings for ResMed ↗

October 12, 2023

Via Benzinga

2 Monster Stocks to Buy Without Any Hesitation ↗

November 07, 2023

Down 33% and 44%, these two stocks look too good to pass up today.

Via The Motley Fool

How Sleep Device Player ResMed Is Gaining Philips' Market Share In Flow Generator Market - Analysts Weigh In ↗

October 27, 2023

Needham analyst Mike Matson reiterated a Buy rating on ResMed Inc. (NYSE: RMD)

Via Benzinga

Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact? ↗

October 27, 2023

Makers of devices to treat obesity-related conditions have struggled recently. Analysts say there's more to the story.

Via Investor's Business Daily

ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2024

October 26, 2023

From ResMed Inc.

Via GlobeNewswire

Earnings Scheduled For October 26, 2023 ↗

October 26, 2023

Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on revenue of $49.83 billion.

Via Benzinga

3 Stocks to Buy From the ‘Buy the Dip’ ETF ↗

October 23, 2023

It’s a lot harder than it looks to buy the dip. Using artificial intelligence to do this makes these three stocks a buy.

Via InvestorPlace

Topics Artificial Intelligence

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2023 ↗

October 12, 2023

Via Benzinga

Exxon Mobil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Thursday ↗

October 12, 2023

Cantor Fitzgerald cut Hyliion Holdings Corp. (NYSE: HYLN) price target from $2 to $1. Cantor Fitzgerald analyst Andres Sheppard downgraded the stock from Neutral to Underweight. Hyliion shares fell...

Via Benzinga

ResMed to Report First Quarter Fiscal 2024 Earnings on October 26, 2023

October 05, 2023

From ResMed Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023 ↗

September 29, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 18, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

September 15, 2023

Friday's session saw 169 companies set new 52-week lows.

Via Benzinga

3 Top Growth Stock Picks Trading at a Massive Bargain ↗

September 13, 2023

These growth stock picks are trading at bargain prices and are well-positioned to rebound and deliver substantial gains in the coming months.

Via InvestorPlace

Stocks That Hit 52-Week Lows On Thursday ↗

September 07, 2023

On Thursday, 283 companies set new 52-week lows.

Via Benzinga

Is It Time to Buy the S&P 500's 3 Worst-Performing August Stocks? ↗

September 07, 2023

The S&P 500 had a rare decline last month.

Via The Motley Fool

Topics Stocks

Sleep Device Player ResMed's Potential Obstacles: Analyst Weighs Obesity Drugs & Philips' Re-Entry ↗

September 06, 2023

Needham upgraded ResMed Inc (NYSE: RMD) from a Hold to Buy rating with a price target of $180

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023 ↗

September 06, 2023

Via Benzinga

ResMed Announces Participation in Upcoming Conferences

September 05, 2023

From ResMed Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For September 5, 2023 ↗

September 05, 2023

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com